BiotechTube

SPT-07A injection

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stroke, Acute

Conditions

Stroke, Acute

Trial Timeline

Jan 20, 2022 → Jan 10, 2024

NCT ID
NCT05159947

About SPT-07A injection

SPT-07A injection is a phase 3 stage product being developed by Sinopharm for Stroke, Acute. The current trial status is unknown. This product is registered under clinical trial identifier NCT05159947. Target conditions include Stroke, Acute.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05159947Phase 3UNKNOWN

Competing Products

20 competing products in Stroke, Acute

See all competitors
ProductCompanyStageHype Score
Osmotic drugsSinopharmPre-clinical
22
Aspirin, ClopidogrelYuhanPre-clinical
23
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
41
SUN13837 + placeboDaiichi SankyoPhase 2
52
DS-1040b + AspirinDaiichi SankyoPhase 1
33
piclozotan low dose + placebo + piclozotan high doseDaiichi SankyoPhase 2
52
DS1040b + PlaceboDaiichi SankyoPre-clinical
23
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
52
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxabanDaiichi SankyoPhase 3
77
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
52
ASP2246Astellas PharmaPhase 1/2
41
Neu2000KWL + Neu2000KWL + Neu2000KWL + PlacebosSun PharmaceuticalPhase 2
52
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
52
Redasemtide + PlaceboShionogiPhase 2
52
StatinShionogiApproved
85
AlteplaseKyowa KirinApproved
85
ONO-2506 + ONO-2506 + ONO-2506Ono PharmaceuticalPhase 2/3
65
AbciximabEli LillyPhase 3
77
AbciximabEli LillyPhase 3
77
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
52

Other Products from Sinopharm

Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboPhase 2
51
Unfractionated heparinPre-clinical
22
Osmotic drugsPre-clinical
22